Dupilumab Improves Symptoms of Anxiety and Depression in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Three Phase 3 Trials (LIBERTY AD SOLO 1 & 2 and ADOL)

Atopic dermatitis (AD) patients have an increased risk of anxiety, depression, and suicide. Dupilumab is approved in certain patients with AD, asthma, and CRSwNP. This post-hoc analysis determined the effect of dupilumab on anxiety and depression in adults and adolescents with moderate-to-severe AD.

Source: Journal of Allergy and Clinical Immunology - January 31, 2020 Category: Allergy & Immunology Authors: Jonathan Silverberg, Weily Soong, Benjamin Lockshin, Abhijit Gadkari, Zhen Chen, Ashish Bansal, Laurent Eckert Source Type: research